Suppr超能文献

日本上市后不良事件救济系统:监管科学、法律体系与临床药理学的融合

The Japanese Postmarketing Adverse Event Relief System: A Confluence of Regulatory Science, the Legal System, and Clinical Pharmacology.

作者信息

Tominaga T, Miyazaki S, Oniyama Y, Weber A D, Kondo T

机构信息

Pharmaceuticals and Medical Devices Agency (PMDA), Chiyoda-ku, Tokyo, Japan.

出版信息

Clin Pharmacol Ther. 2017 Aug;102(2):277-282. doi: 10.1002/cpt.537. Epub 2016 Dec 7.

Abstract

The Japanese Postmarketing Relief System provides for compensation to patients with adverse reactions, based on the acknowledgment that unpredicted adverse events occur inevitably once a drug is marketed. The system also provides new knowledge about the benefit-risk profile of a drug that may be incorporated into product labeling. The system relies on causality assessments that are based on sound clinical pharmacology principles. The system may serve as a model for other countries' healthcare systems.

摘要

日本上市后救济系统规定,鉴于药物上市后不可避免地会出现无法预测的不良事件,应为不良反应患者提供补偿。该系统还能提供有关药物获益-风险状况的新知识,这些知识可能会被纳入产品标签。该系统依赖基于可靠临床药理学原则的因果关系评估。该系统可作为其他国家医疗保健系统的一个典范。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验